Thermo Fisher Scientific CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), PE, eBioscience

Applications and Tested Dilution

Product Specifications

Available Formats

• Unconjugated
• Biotin
• Request custom conjugation

Product Specific Information

Description:
The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2, and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells.

Applications Reported:
The DJR2-4 (a.k.a. 7-8) antibody has been reported for use in flow cytometric analysis.

Applications Tested:
This antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells.
Recommended use: 5 µL (0.25 µg) per test.
A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL.
Cell number should be determined empirically (10⁵–10⁸ cells/test).

Fluorescence Characteristics:
Excitation: 488–561 nm
Emission: 578 nm
Laser compatibility: Blue, Green, Yellow-Green lasers

Filtration:
0.2 µm post-manufacturing filtered.

Target Information

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER):
A death domain-containing receptor for TRAIL, mediating TRAIL-induced apoptosis.
Member of the TNF-receptor superfamily with intracellular death domain.
Activated by TNFSF10/TRAIL/APO-2L and transduces apoptosis signals.
FADD adaptor protein is required for DR5-mediated apoptosis.
Two transcript variants and one non-coding transcript identified.
Overexpression induces apoptosis and activates NF-kappa-B.
Highly expressed in lymphocytes and spleen.
Associated diseases: squamous cell carcinoma, diffuse infiltrative lymphocytosis syndrome.

For Research Use Only.
Not for use in diagnostic procedures.
Not for resale without express authorization.

제품 이미지